Key result
Next-generation sequencing of 242 Hungarian patients with hypertrophic cardiomyopathy identified pathogenic or likely pathogenic variants in 37%, most frequently in the MYBPC3 (61%) and MYH7 (23%) genes.
Why the study?
To perform a nationwide large-scale genetic analysis of a previously unreported, representative hypertrophic cardiomyopathy cohort in Hungary.
Observational (n=242)
Yes
Genetic testing of Hungarian HCM patients reveals MYBPC3 and MYH7 as the most commonly mutated genes, with three specific MYBPC3 mutations suggesting a founder effect.
Supports MYBPC3/MYH7-focused panels in Hungarian HCM; extends population-specific data while leaving generalizability open.
Hypertrophic cardiomyopathy (HCM) is a primary disease of the myocardium most commonly caused by mutations in sarcomeric genes. We aimed to perform a nationwide large-scale genetic analysis of a previously unreported, representative HCM cohort in Hungary. A total of 242 consecutive HCM index patients (127 men, 44 ± 11 years) were studied with next generation sequencing using a custom-designed gene-panel comprising 98 cardiomyopathy-related genes. A total of 90 patients (37%) carried pathogenic/likely pathogenic (P/LP) variants. The percentage of patients with P/LP variants in genes with definitive evidence for HCM association was 93%. Most of the patients with P/LP variants had mutations in MYBPC3 (55 pts, 61%) and in MYH7 (21 pts, 23%). Double P/LP variants were present in four patients (1.7%). P/LP variants in other genes could be detected in ≤3% of patients. Of the patients without P/LP variants, 46 patients (19%) carried a variant of unknown significance. Non-HCM P/LP variants were identified in six patients (2.5%), with two in RAF1 (p.Leu633Val, p.Ser257Leu) and one in DES (p.Arg406Trp), FHL1 (p.Glu96Ter), TTN (p.Lys23480fs), and in the mitochondrial genome (m.3243A>G). Frameshift, nonsense, and splice-variants made up 82% of all P/LP MYBPC3 variants. In all the other genes, missense mutations were the dominant form of variants. The MYBPC3 p.Gln1233Ter, the MYBPC3 p.Pro955ArgfsTer95, and the MYBPC3 p.Ser593ProfsTer11 variants were identified in 12, 7, and 13 patients, respectively. These three variants made up 36% of all patients with identified P/LP variants, raising the possibility of a possible founder effect for these mutations. Similar to other HCM populations, the MYBPC3 and the MYH7 genes seemed to be the most frequently affected genes in Hungarian HCM patients. The high prevalence of three MYBPC3 mutations raises the possibility of a founder effect in our HCM cohort.
No takes yet. Share an insight, caveat, or question.
Sepp et al. (2022) conducted an observational in Hypertrophic cardiomyopathy (HCM) (n=242). Next generation sequencing (98-gene panel) was evaluated on Detection of pathogenic/likely pathogenic (P/LP) variants. Next-generation sequencing of 242 Hungarian patients with hypertrophic cardiomyopathy identified pathogenic or likely pathogenic variants in 37%, most frequently in the MYBPC3 (61%) and MYH7 (23%) genes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: